Cambridge Healthtech Instituteの第2回年次会議

Spatial Biology
(空間生物学)

マルチオミクス解析に新たな一面を加える

2023年3月6 - 7日、PST(米国太平洋標準時)

 

空間生物学の新興技術は、生物学的経路における最適な理解、新しいバイオマーカーや薬剤標的の発見、洞察力に富んだトランスレーショナルリサーチを可能にすることが期待されています。Cambridge Healthtech Instituteの第2回「空間生物学」年次会議では、空間マルチオミクスツールを使用して、腫瘍学、神経学、免疫学などの分子的洞察を明らかにする最新の技術と研究内容を紹介します。

3月6日(月)

Registration and Morning Coffee7:00 am

PLENARY KEYNOTE SESSION: Rx/Dx COLLABORATIONS: STRATEGIES FOR BRINGING TARGETED THERAPIES TO MARKET
基調講演・プレナリーセッション:Rx/Dxのコラボレーション:標的療法の市場投入戦略

8:00 am

Chairperson's Remarks

Edward Abrahams, PhD, President, Personalized Medicine Coalition

8:05 am Plenary Keynote IntroductionPlenary Keynote Introduction

Paul Beresford, PhD, Vice President and General Manager, CDx, Diagnostics and Genomics Group, Agilent Technologies

8:15 am KEYNOTE PRESENTATION:

Precision Medicine, What's So Difficult? The Interplay & Complexities of Pharmaceutical & Diagnostic Partnerships to Deliver the Promise of Precision Medicine

Sarah Hersey, MS, MBA, RAC, Vice President, Precision Medicine, Bristol Myers Squibb Co.

Numerous dynamic intricacies exist between pharmaceutical and diagnostic industries which require careful consideration when deploying precision medicine solutions. This, coupled with technological advances and an evolving regulatory landscape, results in significant complexity. From the push to try to incorporate precision medicine earlier in drug development, through commercialization, what are the potential opportunities as well as hurdles to overcome to enable more effective collaborations to deliver targeted therapies?

8:45 am PANEL DISCUSSION:

Rx/Dx Collaborations: Strategies for Bringing Targeted Therapies to Market

PANEL MODERATOR:

Edward Abrahams, PhD, President, Personalized Medicine Coalition

This session will explore challenges and strategies to discover and develop personalized medicines from the points of view of both the diagnostic and pharmaceutical industries.

PANELISTS:

Christopher Conn, PhD, Director, Diagnostics Strategy, Amgen

Marielena Mata, PhD, Senior Director and Diagnostic Lead, Oncology Program, Pfizer Inc.

David Fabrizio, Vice President, Translational Strategy, Foundation Medicine

Sarah Hersey, MS, MBA, RAC, Vice President, Precision Medicine, Bristol Myers Squibb Co.

Networking Refreshment Break9:30 am

ADVANCES IN SPATIAL TRANSCRIPTOMICS
空間トランスクリプトミクスの進歩

9:45 am

Chairperson's Remarks

Ioannis Vlachos, PhD, Director, Spatial Technologies, Beth Israel Deaconess Medical Center; Assistant Professor, Pathology, Harvard Medical School; Associate Member, Broad Institute of MIT & Harvard

9:50 am

Spatial Tissue Profiling: A Highway from Early Discovery to Translation

Ioannis Vlachos, PhD, Director, Spatial Technologies, Beth Israel Deaconess Medical Center; Assistant Professor, Pathology, Harvard Medical School; Associate Member, Broad Institute of MIT & Harvard

10:20 am

Advancing Bioimaging with DNA Probes

Peng Yin, PhD, Professor, Systems Biology, Harvard Medical School, Wyss Institute, Harvard University

10:50 am

Mechanisms of RNA Localization by Spatial Genomics and Bento

Eugene Yeo, PhD, MBA, Professor, Cellular and Molecular Medicine, University of California, San Diego; Founding Member, Institute for Genomic Medicine

We will explore subcellular RNA localization and mechanisms of how RNA travels by using spatial technologies and a new software package we developed called Bento.

11:20 am Parhelia Omni-Stainer: Simple and Efficient Open Tissue Automation for the Spatial Biology Era

Nikolay Samusik, PhD, CEO, Parhelia Biosciences

As the spatial biology sector explodes, there is a developing need for an effective, reliable, reproducible, and accessible tissue staining solution. Parhelia Bio is making tissue auto-staining accessible to all with new Parhelia Omni-Stainer C12 for coverslip staining and S12 for slide-mounted samples, used in conjunction with the Opentrons OT-2 or other SBS-format liquid handlers for a complete automated tissue staining system. Examples of assays include: IHC, IF/CODEX, Opal, RNAScope and IMC.

Sponsored Presentation (Opportunity Available)11:35 am

Session Break11:50 am

11:55 am LUNCHEON PRESENTATION:See Biology in New Ways with Single-Cell, Spatial, and in situ Multiomics

John Manuel, PA (ASCP), Spatial Science & Technology Advisor, 10x Genomics

Join us to learn how Chromium Single-Cell, Visium Spatial, and Xenium in situ platforms from 10x Genomics can help you push the boundaries of your research. Uncover molecular insights, dissect cell-type differences, investigate the adaptive immune system, detect novel subtypes and biomarkers, and map the epigenetic landscape cell by cell.  Enabling deeper insight into cancer, immunology, and neuroscience, 10x Genomics gives researchers the ability to see biology in new ways.

Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own12:25 pm

Session Break12:55 pm

SPATIAL PROFILING TO STUDY DISEASE BIOLOGY
空間プロファイリングによる疾患生物学研究

1:10 pm

Chairperson's Remarks

Anka Ehrhardt, PhD, Director, Cell-Based Sciences, Merck

1:15 pm

Dissecting Crohn’s Disease Pathology with Spatial Profiling of Myeloid Cell Phenotypes

Alexander C. Klimowicz, PhD, Principal Scientist, Immunology & Respiratory Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc.

1:45 pm

Spatial Atlas of the Human Olfactory Bulb

Douglas Shepherd, PhD, Assistant Professor, Biological Physics, Arizona State University

Understanding how the human brain perceives odorant and how the organization of our olfactory system varies from model systems requires functional measurements, connectivity, and spatial molecular expression. In this talk, I will discuss new scalable 3D imaging and analysis methods to generate highly multiplexed molecular mapping of human tissue, including the olfactory bulb. Using these approaches, we are working towards building a spatial molecular and cell atlas of the olfactory bulb.

2:15 pm

Multi-Modal Analyses of Fibroblast Archetypes in Health and Disease

Rachana N. Pradhan, PhD, Postdoctoral Fellow, Oncology Bioinformatics, Genentech

Fibroblasts are structural cells that regulate tissue architecture, support homeostasis of tissue-resident cells, and play pivotal roles in fibrosis, cancer, autoimmunity, and wound healing. We apply multi-modal single-cell and spatial methods to identify and characterize fibroblast phenotypes across healthy tissues and disease indications. Our integrative analyses of fibroblasts represent an effort into implementing sophisticated single-cell methods toward the discovery of novel fundamental biology which will yield clinical dividends.

Sponsored Presentation (Opportunity Available)2:45 pm

Networking Refreshment Break3:15 pm

30th ANNIVERSARY OF TRI-CON PLENARY KEYNOTE SESSION: GENOMICS INNOVATION
30周年記念TRI-CON基調講演・プレナリーセッション:ゲノムイノベーション

3:40 pm

Chairperson's Remarks

Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing

3:45 pm FIRESIDE CHAT:

Sequences, SynBio, and Sailing: Three Decades of Adventure with J. Craig Venter

Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing

J. Craig Venter, PhD, Founder, Chairman, and CEO, J. Craig Venter Institute

Since his riveting publication on expressed sequence tags in 1991, which galvanized a revolution in genomics, J. Craig Venter has been a dominant figure in the world of genomics and biotechnology. As the first human to have his personal genome completely sequenced, and as the co-founder of Synthetic Genomics and Human Longevity, he is routinely one step ahead of his peers. As we celebrate 30 years of TRI-CON, we’re thrilled to host Dr. Venter who will discuss his life, his many accomplishments, and his vision for the future of precision medicine and the biotech industry.

4:15 pm PANEL DISCUSSION:

30 Years of Genomics Innovation and the Future of Precision Medicine

PANEL MODERATOR:

Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing

Over the past three decades, genomic medicine has been transformed from a distant dream to a clinical reality. With patients suffering genetic diseases and cancer now cured thanks to advances in genomics, cell therapy, genome editing, and computing, the future is bright - but by no means assured. In this TRI-CON keynote panel, we discuss the scientific highlights of an extraordinary journey for practitioners of precision medicine and anticipate where the field is headed.

PANELISTS:

Euan Ashley, PhD, Professor, Genomics & Precision Health, Stanford School of Medicine

J. Craig Venter, PhD, Founder, Chairman, and CEO, J. Craig Venter Institute

Molly He, PhD, CEO & Co Founder, Element Biosciences

Alex Aravanis, MD, PhD, CTO, Senior Vice President, Head of Research and Product Development, Illumina

Welcome Reception in the Exhibit Hall with Poster Viewing5:00 pm

Close of Day6:00 pm

3月7日(火)

Registration and Morning Coffee7:30 am

30th ANNIVERSARY OF TRI-CON PLENARY KEYNOTE SESSION: DIAGNOSTIC INDUSTRY TRENDS
30周年記念TRI-CON基調講演・プレナリーセッション:診断業界の動向

8:00 am

Chairperson's Remarks

Mara G. Aspinall, Managing Director, BlueStone Venture Partners; Professor of Practice, Arizona State University; Advisor, The Rockefeller Foundation

8:05 am PANEL DISCUSSION:

Big Diagnostics: 30 Years of Impact

PANEL MODERATOR:

Mara G. Aspinall, Managing Director, BlueStone Venture Partners; Professor of Practice, Arizona State University; Advisor, The Rockefeller Foundation

Healthcare depends on diagnostics. We all know that diagnostics is the glue that holds the healthcare together and that 70% of medical decisions are informed by a diagnostic - but does that say enough? More than 3.5 million people work in diagnostic industry. The number of companies is at an all-time high. COVID showed the world how valuable a test can be. But with all the changes of the last few years - there have been constants - the industry’s largest players. From the labs to manufacturers, from services to products, there are a few companies that have seen it all. In this panel, we talk to them about the good and bad, challenges and opportunities and most importantly, the impact of the last 30 years.

PANELISTS:

Dave Persing, MD, PhD, Executive Vice President, CSO, Cepheid; CSO, Danaher Diagnostics Platform

Jay Wohlgemuth, MD, CMO and Senior Vice President, R&D, Medical and Population Health, Quest Diagnostics

William G. Morice II, MD, PhD, President & CEO, Mayo Clinic Laboratories; Professor & Past Chair, Mayo Clinic Department of Laboratory Medicine and Pathology; Chair, American Clinical Laboratory Association Board of Directors

Robert J. Bujarski, President and COO, QuidelOrtho Corporation

Cindy Perettie, Head, Roche Molecular Labs

Transition to Sessions9:00 am

SPATIAL ANALYSIS OF THE TUMOR MICROENVIRONMENT
腫瘍微小環境における空間解析

9:05 am

Chairperson's Remarks

Anka Ehrhardt, PhD, Director, Cell-Based Sciences, Merck

9:10 am

Exploring the Spatial and Single-Cell Tumor Microenvironment across Platforms

Anna Elz, Manager, Fred Hutch Innovation Lab, Fred Hutchinson Cancer Research Center

The ability to accurately assess cellular compositions and spatial organization of the tumor microenvironment are critical for development of improved cancer therapeutic strategies. New developments in single-cell sequencing and spatial transcriptomics that are compatible with fixed tissues are enabling powerful new study designs. Here, I will describe our progress in benchmarking these approaches and I will talk about how we are taking advantage of these new fixation-based methods to facilitate studies that require information about the detailed cellular architectures of human cancers.

9:40 am

Spatial CRISPR Genomics (Perturb-map) Identifies Regulators of the Tumor Microenvironment

Maxime Dhainaut, PhD, Postdoctoral Research Fellow, Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai

The cellular architecture and immune composition of a tumor have a major impact on cancer outcome. We developed Perturb-map, a platform for functional genomics within a tissue at single-cell resolution with spatial architecture preserved. We used Perturb-map to knock out dozens of genes in parallel in preclinical cancer models and simultaneously assess how each gene influences tumor growth, histopathology and immune composition of the tumor microenvironment.

Sponsored Presentation (Opportunity Available)10:10 am

Coffee Break in the Exhibit Hall with Poster Viewing10:40 am

11:25 am

Analytical Assay Design for Drugs with Complex MOA

Anka Ehrhardt, PhD, Director, Cell-Based Sciences, Merck

Potency assays are representative of the drug’s mechanism of action (MOA) and are designed to verify consistent biological activity. Many modern oncology drugs are designed to support and enhance the body’s defenses and are aimed to act specifically at the tumor. The direct (micro) environment of the tumor, therefore, typically encircles the key elements of the drug MOA which need to be represented in potency assays.

11:55 am

Systemic Approaches to Dissect Tissue Structure and Study Cell-Cell Interactions from Spatial Transcriptomics Data

Kyoung Jae Won, PhD, Associate Professor, Computational Biomedicine, Cedars Sinai Medical Center

Sponsored Presentation (Opportunity Available)12:25 pm

Session Break12:55 pm

Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own1:00 pm

Refreshment Break in the Exhibit Hall with Poster Viewing1:30 pm

Close of Conference2:00 pm

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
English

カンファレンスプログラム

2023年3月6-7日

Implementing Precision Medicine

Digital Medicine

At-Home & Point-of-Care Diagnostics

Liquid Biopsy

Spatial Biology

2023年3月7-8日

Precision Health

Diagnostics Innovation and Market Access

Infectious Disease Diagnostics

Advanced Diagnostics for Precision Oncology

Single-Cell Multiomics